Despite the trial failure, Sarepta will still seek full approval of AMONDYS 45 and VYONDYS 53 in DMD from the FDA.

At the European Society for Medical Oncology (ESMO) 2025 event, held in Berlin, Germany, between 17-21 October, Celcuity ...

While AstraZeneca's gefurulimab offered significant improvements to MG-ADL scores, it was bested by a variety of ...

The company’s stock rose significantly after it announced the full Phase I/II data. Image credit: Lightspring / Shutterstock.com. Intensity Therapeutics’ stock has risen nearly 400% after its oncology ...

Accurately tracking trial initiations has often been a challenge because start dates are not always disclosed or are reported incorrectly. Credit: Ihar Halavach via Shutterstock.com. According to ...

In a Phase I trial, biomarkers seem to suggest the potential for a once or twice yearly dosing of Wave’s siRNA for weight ...

AbbVie's Rinvoq will have to come up against Pfizer’s prospective and Incyte’s approved JAK inhibitors in the non-segmental ...

Aditya Kotta discussed the biotech funding environment and market trends at OCTSC meeting, in San Diego, California, US. Credits: Athanasios Psimadis / Arena International. The biotech sector has ...

The app helps sites and patients stay synchronised, supporting compliance. Credit: SOMKID THONGDEE/Shutterstock.com. US-based software company Suvoda has launched a unified patient mobile app to ease ...

Despite ADX-629 meeting all its endpoints in a Phase II trial, Aldeyra is culling the asset as part of a pipeline ...

Zenas BioPharma’s investigational relapsing multiple sclerosis (RMS) asset, obexelimab, has met its primary endpoint in the Phase II MoonStone trial. Image credit: OksanaFedorchuk via Shutterstock.com ...

Analysts at GlobalData forecast that GCG/GLP-1RA mazdutide will become a blockbuster seller in China for Innovent by 2030.